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Abstract
Background: There is limited evidence on the role of an anti‐/pro‐inflammatory
diet in the prevention of non‐alcoholic fatty liver disease (NAFLD). We aimed
(i) to assess the anti‐inflammatory diet profile and its association with tran-
sient elastography parameters, including liver stiffness measurement (LSM)
and controlled attenuation parameter (CAP), and (ii) to analyse the re-
lationship between the anti‐inflammatory diet and surrogate markers of liver
disease in a multiethnic US population.
Methods: A cross‐sectional study was conducted on a nationally representative
population of 4189 US adults aged 20–80 years. A FibroScan® 502 V2 device
(Echosens) was used to estimate the CAP and LSM. Liver markers, including
the aspartate transaminase (AST) to alanine transaminase (ALT) ratio, fatty
liver index (FLI) and fibrosis‐4 score, were also calculated. The Dietary In-
flammatory Index (DII) was calculated using a 24‐h diet recall.
Results: Lower DII scores (anti‐inflammatory diet) were associated with a
lower AST:ALT ratio (p< 0.001) and FLI (p< 0.036) after adjusting for
covariates. Linear regression analysis revealed that gamma‐glutamyl trans-
ferase levels (β = 1.702, 95% confidence interval [CI] = 0.325–3.080, p= 0.015),
ALT levels (β= −0.616, 95% CI = −1.097 to −0.135, p= 0.012), AST:ALT
ratio (β = 0.025, 95% CI = 0.014–0.036, p< 0.001) and FLI (β = 1.168, 95%
CI = 0.224–2.112, p= 0.015) were significantly associated with the DII in the
multivariable‐adjusted model. Participants in the highest anti‐inflammatory
tertile had the lowest odds ratio (OR) for NAFLD assessed by FLI in both
unadjusted (OR= 0.652, 95% CI = 0.539–0.788, p ≤ 0.001) and adjusted mod-
els (OR= 0.722, 95% CI = 0.537–0.972, p= 0.032). For the transient elasto-
graphy parameters (LSM and CAP), no significant associations were
identified.
Conclusions: There was no relationship between the transient elastography
parameters and the anti‐inflammatory diet profile, although our study showed
an association between higher pro‐inflammatory properties of diet and poorer
hepatic health assessed by surrogate markers of liver disease. Therefore,
strategies to promote an anti‐inflammatory diet should be considered to pre-
vent NAFLD in adults.
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Key points
• An anti‐inflammatory diet was significantly associated with lower aspartate
transaminase:alanine transaminase ratio and fatty liver index (FLI).
• Higher pro‐inflammatory properties of diet were associated with an in-
creased risk of non‐alcoholic fatty liver disease (NAFLD) assessed by FLI.
• Strategies to promote an anti‐inflammatory diet should be considered to
prevent NAFLD in adults.
INTRODUCTION
Non‐alcoholic fatty liver disease (NAFLD) has become the
most common chronic liver disease, ranging from simple
steatosis to non‐alcoholic steatohepatitis (NASH) with
varying amounts of fibrosis and cirrhosis.1 The estimated
prevalence has increased rapidly and, in the USA and
Europe, it is approximately 30%.1,2 Worryingly, it has been
postulated that the overall NAFLD prevalence among the
adult population is projected to be 33.5% in 2030.3 NAFLD
has been recognised as an important predictor of cardio-
vascular disease events because the presence of NAFLD is
significantly associated with a 64% increased risk of cor-
onary artery disease and stroke.4 Moreover, a recent meta‐
analysis showed that NAFLD is a predictor of increased
all‐cause mortality.5
Considering the burden of disease, screening for
NAFLD is important for preventing progression of the
disease to advanced fibrosis. Although liver biopsy is
considered the gold standard in the evaluation of
NAFLD, it is neither practical, nor feasible to perform
liver biopsies in large populations and therefore has
been partially replaced by non‐invasive methods.
Transient elastography is a simple‐to‐perform imaging
modality with high accuracy for assessing liver stiffness
and hepatic fat deposition when performed by
FibroScan, as recommended by the American Asso-
ciation for the Study of Liver Diseases.6 Transient
elastography estimates the liver stiffness measurement
(LSM) and controlled attenuation parameter (CAP),
which are markers of hepatic fibrosis and steatosis,
respectively.7,8 Furthermore, other non‐invasive mar-
kers of liver injury with high sensitivity and accuracy,
such as the aspartate transaminase:alanine transami-
nase (AST:ALT) ratio,9 the fatty liver index (FLI)10
and the fibrosis‐4 score (FIB4),11 which include a
combination of clinical and routine parameters, may be
useful surrogate measures of NAFLD. These simple
measurements might be indicated for screening to
identify patients at high risk for fatty liver disease in the
general healthy population.12
NAFLD is a complex disease that appears to be
modulated by the interplay of diverse mechanisms, including
metabolic, genetic, environmental and gut microbial fac-
tors.13 Among the modifiable factors, it has been demon-
strated that dietary factors are linked to hepatic health;
however, there is limited evidence on the role of diet quality
in the prevention of NAFLD. Considering that NAFLD has
been associated with a systemic and hepatic proin-
flammatory state and that inflammatory cytokines and
chemokines, including tumor necrosis factor‐α, interleukin‐6
and high‐sensitivity C‐reactive protein (hs‐CRP), are in-
creased in patients with NAFLD and NASH,14 it should be
hypothesised that an anti‐inflammatory diet could lead to an
improvement in liver status. Previous studies have shown
that the inflammatory potential of the diet is associated with
mortality, metabolic syndrome and hepatic markers and
therefore might be an important predictor of NAFLD.15–20
Furthermore, it has been shown that theMediterranean diet,
a diet characterised by an anti‐inflammatory dietary pattern,
might have a beneficial role in the onset and severity of
NAFLD.21–23 However, the relationship between the Diet-
ary Inflammatory Index (DII), a literature‐derived dietary
index that was developed to predict inflammation,24 and the
LSM and CAP assessed by transient elastography has not
been investigated previously.
Therefore, the present study aimed (i) to assess the
anti‐inflammatory diet profile measured by the DII and
its association with transient elastography parameters,
including LSM and CAP, and (ii) to analyse the re-
lationship between the anti‐inflammatory diet and
surrogate markers of liver disease in a multiethnic US
population using the population‐based National Health
and Nutrition and Examination Surveys (NHANES;
https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/
overview.aspx?BeginYear=2017) from 2017 to 2018.
METHODS
Design and study population
This cross‐sectional study used data from NHANES
2017–2018. The data were acquired from a stratified
multistage probability sample of a non‐institutionalised
civilian population in the USA. Ethical approval was
obtained through the National Center for Health Sta-
tistics Research Ethics Review Board (CDC, 2016) re-
search ethics review board. Further approval was not
sought for the study because the data used were free of
personal identifiers. All procedures conformed to the
tenets of the Helsinki Declaration of 1975 (revised in
2013) and written informed consent was obtained from
all participants.
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Participants
Of the 9952 participants in the NHANES (2017–2018) who
were aged 0–80 years, 4907 (restricted >20 years old) were
assessed according to the inclusion criteria: (i) complete
metabolic and liver function parameters; (ii) a complete
transient elastography test; and (iii) a complete 24‐h recall.
For analyses evaluating the FLI and the FIB4, we ad-
ditionally excluded persons with missing data on one or
more components of the FLI and FIB4 (n=426). Ad-
ditionally, we exclude participants with positive for HBsAg/
IgG anti‐HBc/anti‐HCV/anti‐HIV antibodies (n=237)
and pregnancy (n=55). Data from 4189 participants were
analysed.
Instrumentation and measurements
All measurement procedures were taken from the pub-
lished guidelines and procedures used by NHANES
(https://wwwn.cdc.gov/nchs/nhanes). Anthropometric
data (body mass, height and waist circumference) were
collected by trained health technicians. Body mass index
(BMI) was calculated as weight (kg) divided by height
(m)2. Participants were tested on routine cardiometabolic
parameters. Triglycerides, total cholesterol, high‐density
lipoprotein (HDL), glucose, glycated hemoglobin, total
bilirubin, hs‐CRP, ALT, AST and γ‐glutamyl transferase
(GGT) concentrations were measured on the Cobas 6000
(c501 module) analyser (Roche) using a standard pro-
tocol by highly trained medical personnel in the mobile
examination centre (MEC). Insulin resistance was as-
sessed using the homeostasis model assessment of insulin
resistance (HOMA‐IR), according to the equation: fast-
ing glucose (mmol L–1) × fasting insulin (mU L–1)/22.5.
Comorbidity data including hypertension (defined as
systolic blood pressure ≥140mmHg, diastolic blood pres-
sure 90mmHg, or on treatment with an antihypertensive
agent), low HDL cholesterol (defined as a HDL choles-
terol <50mg dl–1 for women and <40mg dl–1 for men),
obesity (defined as a value ≥30 kg m–2) and diabetes (de-
fined as a fasting plasma glucose ≥126mg dl–1 or treat-
ment with a hypoglycaemic agent or insulin) were also
evaluated. Sociodemographic characteristics were all as-
sessed by self‐report during an in‐home interview, such as
age, sex, race/ethnicity (non‐Hispanic White; non‐
Hispanic Black; Mexican American or other Hispanic;
and other, including multiracial) and citizenship status
(citizen by birth, citizen by naturalisation or non‐citizen).
Minutes sedentary activity was measured based on the
World Health Organization (WHO)'s Global Physical
Activity Questionnaire.25 Smoking was based on self‐
reporting. For assessment of the diet, 24‐h recall was ap-
plied by a skilled assessor throughout the MEC as de-
scribed previously.26 The level of alcohol intake was
evaluated through the use of diet 24‐h recall (drinkers
were defined with respect to the consumption of ≥40 g).
Liver markers
The AST:ALT ratio was calculated by dividing the serum
AST by the ALT. We used the published cut‐off of AST/
ALT ratio ≤1 cut‐off for excluding advanced fibrosis.9
The FLI score is an index that was designed to assess
hepatic steatosis and was calculated using10:
Participants with FLI measurements of ≥60 were ca-
tegorised in the hepatic steatosis group.27 The FIB4 was
calculated using: age (years) × AST [U L–1]/(platelets
[109 L–1] × (ALT [U L–1])1/2). We used the cut‐off value
of 1.45 because it was shown to have a negative pre-
dictive value of 90% for advanced fibrosis.11
Transient elastography
The transient elastography measurements were obtained in
the NHANES MEC, using the FibroScan® 502 V2 Touch
(Echosens) equipped with a medium or extra‐large wand
(probe), approved by the Food and Drug Administration.
Participants were excluded if they (i) were unable to lie down
on the exam table; (ii) were pregnant (or unsure if pregnant)
at the time of their exam, or a urine sample could not be
obtained to test for pregnancy; (iii) had an implanted elec-
tronic medical device; or (iv) were wearing a bandage or had
lesions on the right side of their abdomen by the ribs (where
measurements would be taken). Liver tissue examination
was performed with the subject lying supine. The device
estimates liver fibrosis and steatosis assessed by LSM (kPa)
and CAP (dB m–1), respectively. LSM and CAP scores of
each participant was obtained simultaneously in the ex-
amination. Results were included in the final analysis only if
the following three criteria were met: fasting time of at least
3 h, 10 or more complete LMSmeasures and an interquartile
range less than 30% of the median LSM value. A detailed
description of quality assurance and quality control mea-
sures considered for this component can be found in the
Procedures Manual (https://wwwn.cdc.gov/nchs/data/
nhanes/2017-2018/manuals/2018.pdf). The diagnosis of
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The DII
The DII has been described previously.24 It is based on a
review of the literature published up to 2010 linking diet
and inflammatory markers. To calculate DII for the par-
ticipants in the present study, the dietary data were first
linked to the regionally representative world database,
which provided a robust mean± SD estimate for each
parameter. These then became the multipliers for expres-
sing an individual's exposure relative to the ‘standard glo-
bal mean’ as a Z score. This was achieved by subtracting
the ‘standard global mean’ from the amount reported and
dividing this value by the SD. To minimise the effect of
‘right skewing’, this value was then converted to a centred
percentile score. This score, for each food parameter for
each individual, was then multiplied by the respective food
parameter effect score, derived from the literature review,
to obtain a food parameter‐specific DII score for each in-
dividual. All the food parameter‐specific DII scores are
then added together to create each participant's global DII
score. Overall, 26 food parameters, including energy, pro-
tein, carbohydrate, total fat, saturated fatty acid, mono-
unsaturated fatty acid, polyunsaturated fatty acid,
cholesterol, fibre, vitamin E, vitamin A, beta carotene,
niacin, riboflavin, thiamine, vitamin B6, folic acid, vitamin
B12, vitamin C, vitamin D, magnesium, iron, zinc, sele-
nium, caffeine and alcohol, to calculate the global DII.
Positive values represent a pro‐inflammatory diet, whereas
negative values represent an anti‐inflammatory diet. DII
scores range from 3.09 (maximally pro‐inflammatory) to
−4.70 (maximally anti‐inflammatory).
Statistical analysis
Data were analysed with SPSS, version 22.0 (IBM
Corp.). The Kolmogorov–Smirnov test was used to
verify data distribution normality. Data were expressed
as the mean ± SD for continuous variables and as fre-
quencies and percentage for categorical variables. The
DII was analysed both as a continuous variable and a
categorised variable based on tertiles. Unadjusted dif-
ferences in clinical and demographic characteristics by
DII tertiles characteristics were compared using a one‐
way analysis of variance for continuous variables, and
chi‐squared tests for categorical variables. Analysis of
covariance was also used to examined differences in liver
markers and LSM and CAP by DII tertiles after ad-
justing by sex, age, race, citizenship status, energy intake,
alcohol intake, smoking, sedentary activity, hyperten-
sion, low HDL levels, obesity and type 2 diabetes mel-
litus. Linear regression analyses were conducted to
determine the association of the continuous DII score
with liver markers and transient elastography parameters
unadjusted and adjusted for covariates. Furthermore,
multivariable logistic regression analyses were used to
estimate the odds ratios (OR) for NAFLD for
participants with an anti‐inflammatory diet vs. a pro‐
inflammatory diet (the reference category) in separate
models, with one unadjusted and the other after adjust-
ing for the aforementioned confounding factors. P < 0.05
was considered statistically significant.
RESULTS
Characteristics of the study population by DII
tertiles
The mean ± SD age of the study participants was
50.96 ± 17.36 years and 50.9% were female. The clinical
and demographic characteristics of the participants ac-
cording to the DII tertiles are shown in Table 1. There
were significant differences in the study variables ac-
cording to these DII tertiles. A lower DII score (anti‐
inflammatory diet) was associated with better anthro-
pometric data profiles, including lower body mass
(p= 0.012), BMI (p < 0.001) and waist circumference
(p< 0.001). For cardiometabolic factors, participants
with lower DII scores had lower HOMA‐IR and hs‐CRP
values (p= 0.032 and p< 0.001, respectively). In terms of
liver markers, there were also significant differences in
ALT values (p= 0.002), AST:ALT ratio (p< 0.001) and
FLI (p< 0.001) between DII tertiles. Note that a lower
DII score was associated with lower CAP values
(p= 0.004). Statistically significant differences were also
identified between the DII tertiles and race/ethnicities
(p< 0.001), citizenship status (p< 0.001), the presence of
low HDL levels (p< 0.001), obesity (p< 0.001) and dia-
betes mellitus (p= 0.028), as well as alcohol intake
(p< 0.001) and smoking habits (p = 0.004). For dietary
factors, higher intakes of energy (p< 0.001), proteins
(p< 0.001), carbohydrates (p< 0.001), dietary fibre
(p< 0.001) and fats (p< 0.001) were observed in the anti‐
inflammatory group than in the pro‐inflammatory group.
Associations between liver markers, transient
elastography and the DII
Differences in the DII tertiles on liver markers and LSM
and CAP adjusted by sex, age, race, citizenship status,
energy intake, alcohol intake, smoking, sedentary activ-
ity, hypertension, low HDL levels, obesity and diabetes
mellitus are shown in Table 2. There were significant
differences in the AST:ALT ratio (p < 0.001) and FLI
(p< 0.036) between DII tertiles.
The beta estimates and 95% CI values for the asso-
ciation between the DII, liver markers and transient
elastography parameters are presented in Table 3. Un-
adjusted linear regression analysis revealed that ALT
levels (β =−0.729, 95% confidence interval [CI] = −1.090
to 0.367, p< 0.001), AST levels (β= −0.362, 95%
CI = −0.638 to 0.087, p= 0.010), AST:ALT ratio
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TABLE 1 Clinical and demographic characteristics of the study population by Dietary Inflammatory Index tertiles
Dietary inflammatory index
Tertile 1 (anti‐inflammatory) Tertile 2 Tertile 3 (pro‐inflammatory)
p valueCharacteristics n Mean SD n Mean SD n Mean SD
DII score 1396 −1.531 0.795 1397 0.226 0.392 1396 1.593 0.488 <0.001
Men/women, n (%) 826 (40.2)/570 (26.8) 677 (32.9)/720 (33.8) 554 (26.9)/842 (39.5) <0.001
Anthropometric
Age (years) 1396 51.31 17.11 1397 50.72 17.20 1396 50.86 17.77 0.639
Body mass (kg) 1388 81.13 20.82 1390 83.40 22.64 1390 83.19 23.23 0.012
Height (cm) 1389 168.14 10.00 1391 166.57 10.06 1389 165.07 9.94 <0.001
Body mass index (kg m–2) 1386 28.59 6.44 1389 29.89 6.96 1389 30.46 7.87 <0.001
Waist circumference (cm) 1361 98.32 15.66 1366 101.02 16.92 1364 101.70 17.59 <0.001
Cardiometabolic
Triglycerides (mg dl–1) 1316 148.04 122.13 1322 147.24 127.97 1328 141.68 105.42 0.324
Total cholesterol (mg dl–1) 1321 189.08 41.14 1330 189.45 40.15 1333 187.80 41.26 0.552
HDL cholesterol (mg dl–1) 1321 53.73 14.91 1330 53.21 15.57 1333 52.70 16.27 0.234
Glucose (mg dl–1) 1316 100.73 34.70 1322 102.86 36.79 1328 103.05 36.04 0.182
HbA1c (%) 1345 5.78 0.97 1358 5.87 1.13 1350 5.86 1.10 0.066
HOMA‐IR 598 2.88 2.21 618 3.23 2.46 626 3.05 2.25 0.032
Total bilirubin (µmol L–1) 1317 8.00 4.75 1323 7.88 4.71 1327 7.77 4.52 0.435
hsC‐reactive protein (mg L–1) 1313 3.12 6.36 1323 3.69 5.63 1329 5.07 9.33 <0.001
Liver markers
Glutamyl transferase (IU L–1) 1317 30.27 33.80 1322 33.21 48.70 1328 32.56 52.21 0.220
Alanine aminotransferase (IU L–1) 1317 23.21 14.97 1322 22.68 16.67 1328 21.04 17.40 0.002
Aspartate aminotransferase (IU L–1) 1309 22.38 10.04 1318 21.78 12.81 1327 21.56 14.15 0.218
AST:ALT ratio 1309 1.09 0.36 1318 1.11 0.40 1327 1.17 0.41 <0.001
FLI 842 55.61 33.56 858 62.47 33.92 884 63.55 33.08 <0.001
FIB‐4 1309 1.13 0.67 1318 1.10 0.75 1326 1.12 0.79 0.551
Liver ultrasound transient elastography
LSM (kPa) 1396 5.78 4.45 1397 5.87 5.20 1396 6.02 4.77 0.400
Stiffnessinterquartile range (IQR) 1394 1.00 2.77 1395 1.00 2.06 1394 1.03 1.92 0.580
CAP (dB m–1) 1396 260.47 58.95 1397 266.75 59.14 1396 267.23 61.36 0.004
CAP interquartile range (IQR) 1394 38.21 20.07 1395 37.71 20.94 1394 37.53 19.69 0.851
Race/ethnicities, n (%)
Mexican American 212 (38.3) 204 (36.8) 138 (24.9) <0.001
Other Hispanic 130 (34.1) 135 (35.4) 116 (30.4)
Non‐Hispanic White 480 (32.4) 501 (33.7) 504 (33.9)
Non‐Hispanic Black 269 (27.1) 300 (30.2) 423 (42.6)
Other race, including multi‐racial 305 (39.3) 257 (33.1) 215 (27.7)
Citizenship status, n (%)
Citizen by birth 1177 (32.3) 1192 (32.7) 1272 (34.9) <0.001
(Continues)
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(β= 0.024, 95% CI = 0.015–0.033, p< 0.001), FLI
score (β= 2.489, 95% CI = 1.573–3.404, p< 0.001) and
CAP (β= 1.969, 95% CI = 0.680–3.257, p= 0.003) were
significantly associated with the DII. However, only
GGT levels (β = 1.702, 95% CI = 0.325–3.080, p= 0.015),
ALT levels (β =−0.616, 95% CI = −1.097 to −0.135,
p= 0.012), AST:ALT ratio (β = 0.025, 95%
CI = 0.014–0.036, p< 0.001) and FLI score (β = 1.168,
95% CI = 0.224–2.112, p= 0.015) remained significant
after adjusting for potential covariables. For transient
elastography parameters (LSM and CAP), no significant
associations were identified.
Risk of NAFLD and DII
To further investigate the relationship between the DII
and NAFLD using hepatic health indices, we tested
multiple logistic regression models (Table 4). Associa-
tions between the DII tertiles and the risk of having
NAFLD by the AST:ALT ratio (p< 0.001) and LSM
(p= 0.045) were demonstrated; these associations did not
persist after adjusting for confounding factors. Partici-
pants in the highest anti‐inflammatory tertile had the
lowest OR for NAFLD by FLI in both unadjusted
(OR= 0.652, 95% CI = 0.539–0.788, p< 0.001) and ad-
justed models (OR= 0.722, 95% CI = 0.537–0.972,
p= 0.032). No significant associations were found be-
tween the DII tertiles and the risk of having NAFLD
assessed by LSM and CAP.
DISCUSSION
The present study was the first to evaluate the possible
relationship of the anti‐inflammatory diet profile mea-
sured by the DII and liver status assessed by LSM and
CAP using transient elastography. Additionally, we ex-
amined the association between the DII and other non‐
invasive surrogate markers of liver disease (AST:ALT
ratio, FLI score and FIB‐4 score) in a multiethnic US
population. Our findings revealed a lack of association
between LSM and CAP parameters and the anti‐
inflammatory diet profile. However, we observed that an
anti‐inflammatory diet was significantly associated with a
lower AST:ALT ratio and FLI after adjusting for po-
tential covariables, supporting the influence of dietary
inflammatory potential on liver status. Additionally, we
TABLE 1 (Continued)
Dietary inflammatory index
Tertile 1 (anti‐inflammatory) Tertile 2 Tertile 3 (pro‐inflammatory)
p valueCharacteristics n Mean SD n Mean SD n Mean SD
Citizen by naturalisation 214 (40.1) 199 (37.3) 121 (22.7)
Non‐citizen 2 (28.6) 3 (42.9) 2 (28.6)
Comorbidities, n (%)
Hypertension 145 (36.6) 129 (32.6) 122 (30.8) 0.278
Low HDL levels 308 (26.2) 407 (34.7) 459 (39.1) <0.001
Obesity 701 (28.8) 845 (34.8) 884 (36.4) <0.001
Diabetes mellitus 194 (29.1) 226 (33.9) 247 (37.0) 0.028
Lifestyle factors, n (%)
Alcohol intake (≥40 g) 143 (43.6) 118 (36.0) 67 (20.4) <0.001
Smoking 564 (31.7) 573 (32.3) 644 (36.2) 0.004
Minutes of sedentary activities, min 1387 327.4 193.4 1390 327.4 202.2 1381 332.7 202.0 0.723
Dietary factors
Energy (kcal) 1396 2751.0 1187.5 1397 2088.2 761.9 1396 1491.3 635.7 <0.001
Protein (g) 1396 108.4 49.6 1397 78.11 32.00 1396 52.15 23.95 <0.001
Carbohydrate (g) 1396 321.9 148.4 1397 242.1 100.0 1396 178.2 90.2 <0.001
Dietary fibre (g) 1396 26.5 11.6 1397 15.6 6.6 1396 8.5 4.4 <0.001
Fat (g) 1396 110.0 59.9 1397 84.7 40.3 1396 60.0 31.8 <0.001
Note: In bold: p < 0.05 (comparison between lowest and highest DII).
Abbreviations: AST/ALT, aspartate aminotransferase/alanine aminotransferase; CAP, controlled attenuation parameter; DII, Dietary Inflammatory Index; FLI, fatty
liver index; FIB‐4, fibrosis index based on four factors; HbA1c, haemoglobin A1c; HDL, high‐density lipoprotein; HOMA‐IR, homeostatic model assessment‐insulin
resistance; IQR, interquartile rate; LSM, liver stiffness measurement.
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p valueMean SD Mean SD Mean SD
Liver markers
Glutamyl transferase (IU L–1) 30.25 32.72 31.76 45.15 33.19 56.26 0.095
Alanine aminotransferase (IU L–1) 23.21 15.08 22.52 16.48 21.08 17.91 0.198
Aspartate aminotransferase (IU L–1) 22.46 10.24 21.76 13.19 21.44 13.96 0.691
AST:ALT ratio 1.09 0.36 1.11 0.41 1.17 0.41 0.001
HOMA‐IR 2.85 2.24 3.26 2.47 3.13 2.27 0.141
FLI 56.38 33.31 63.39 33.22 64.60 32.70 0.036
FIB‐4 1.13 0.67 1.09 0.77 1.11 0.79 0.699
Liver ultrasound transient elastography
LSM (kPa) 5.72 4.13 5.95 5.64 6.04 4.94 0.397
CAP (dB m–1) 261.91 58.98 267.32 59.09 267.83 61.80 0.337
Note: In bold: p < 0.05 (comparison between lowest and highest DII).
Abbreviations: AST/ALT, aspartate aminotransferase/alanine aminotransferase; CAP, controlled attenuation parameter; DII, Dietary Inflammatory Index; FLI, fatty
Liver Index; FIB‐4, fibrosis index based on four factors; HOMA‐IR, homeostatic model assessment‐insulin resistance; LSM, liver stiffness measurement.
aThe multivariable models were adjusted with sex, age, race, citizenship status, energy intake, alcohol intake, smoking, sedentary activity, hypertension, low HDL levels,
obesity and diabetes mellitus.





β 95% CI p value β 95% CI p value
Liver markers
Glutamyl transferase (IU L–1) 0.818 −0.190 to 1.825 0.112 1.702 0.325–3.080 0.015
Alanine aminotransferase (IU L–1) −0.729 −1.090 to −0.367 <0.001 −0.616 −1.097 to −0.135 0.012
Aspartate aminotransferase (IU L–1) −0.362 −0.638 to −0.087 0.010 −0.294 −0.673 to 0.085 0.129
AST:ALT ratio 0.024 0.015–0.033 <0.001 0.025 0.014–0.036 <0.001
HOMA‐IR 0.059 −0.015 to 0.133 0.118 0.077 −0.009 to 0.163 0.080
FLI 2.489 1.573–3.404 <0.001 1.168 0.224–2.112 0.015
FIB‐4 −0.005 −0.022 to 0.011 0.549 0.003 −0.015 to 0.020 0.743
Liver ultrasound transient elastography
LSM (kPa) 0.086 −0.018 to 0.190 0.104 0.138 −0.010 to 0.286 0.068
CAP (dB m–1) 1.969 0.680–3.257 0.003 0.974 −0.580 to 2.527 0.219
Abbreviations: AST/ALT, aspartate aminotransferase/alanine aminotransferase; CAP, controlled attenuation parameter; FLI, fatty liver index; FIB‐4, fibrosis index
based on four factors; HOMA‐IR, homeostatic model assessment‐insulin resistance; LSM, liver stiffness measurement.
aThe multivariable models were adjusted with sex, age, race, citizenship status, energy intake, alcohol intake, smoking, sedentary activity, hypertension, low HDL levels,
obesity and diabetes mellitus. In bold: p < 0.05.
found that participants that consumed a proin-
flammatory diet had an increased risk of NAFLD as-
sessed by FLI as a surrogate marker, suggesting that diet‐
induced inflammation may increase the development of
NAFLD.
Limited studies have explored the role of the in-
flammatory potential of diet on non‐invasive markers of
NAFLD.15–17 The FLI is a non‐invasive and inexpensive
measure of fatty liver that may be easily performed in a large
population and has been previously validated in the
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multiethnic NHANES population.12 Our results are re-
inforced by the ATTICA population‐based study conducted
in 3402 adults from the Greek population, which showed
that the dietary anti‐inflammation index was inversely as-
sociated with NAFLD, when applying indices with NAFLD
cut‐offs including the FLI.15 Cantero et al.16 also showed
that a higher DII was associated with a higher degree of liver
damage assessed by a FLI>60 in adults within the PRE-
DIMED study. Similarly, a previous study from the
NHANES also demonstrated significant associations be-
tween increasing DII score and prevalent fatty liver eval-
uated by the FLI.17 Additionally, we demonstrated that the
ALT:AST ratio, an inexpensive and non‐invasive liver
marker, was also associated with the DII score. Similar to
these data, the PREDIMED study found that a pro‐
inflammatory diet was positively associated with relevant
liver markers such as ALT and AST levels.16 Similarly, a
prospective study showed a relationship between perceived
high salt intake, which has been positively associated with
inflammation, and a higher future risk of NAFLD.30 Taken
together, data from the literature and our results indicate
that subjects that consume a pro‐inflammatory diet might be
at risk for fatty liver.
To date, most previous work has focused on liver mar-
kers, which include a combination of clinical and routine
parameters, whereas, to the best of our knowledge, the effect
of dietary inflammatory potential on liver status assessed by
LSM and CAP measures has not been previously in-
vestigated. We found that adults in the highest anti‐
inflammatory tertile had significantly lower CAP scores than
those in the pro‐inflammatory tertile, and CAP values were
also significantly associated with DII scores. However, these
associations did not remain significant after adjusting for
multiple potential covariables. Although our results did not
support a relevant role of the DII on CAP and LSM mea-
sures in a US study cohort, further studies in independent
populations would be necessary to support these preliminary
findings.
Our results highlight that evaluating the inflammatory
potential of the diet might be essential for the early
TABLE 4 Results from the logistic regression models that evaluated non‐alcoholic fatty liver disease (NAFLD) using hepatic health indices by
Dietary Inflammatory Index tertiles
Dietary inflammatory index
NAFLD by AST‐ALT ratio cut‐off
Unadjusted Adjusteda
OR 95% CI p value OR 95% CI p value
Tertile 1 (anti‐inflammatory) 0.689 0.588–0.807 <0.001 0.808 0.642–1.018 0.070
Tertile 2 (anti‐inflammatory) 0.733 0.626–0.859 <0.001 0.858 0.702–1.050 0.137
Tertile 3 (pro‐inflammatory) 1.0 (Reference)
NAFLD by FLI cut‐off
Tertile 1 (anti‐inflammatory) 0.652 0.539–0.788 <0.001 0.722 0.537–0.972 0.032
Tertile 2 (anti‐inflammatory) 0.991 0.819–1.200 0.929 1.011 0.777–1.317 0.934
Tertile 3 (pro‐inflammatory) 1.0 (Reference)
NAFLD by FIB‐4 cut‐off
Tertile 1 (anti‐inflammatory) 1.009 0.846–1.204 0.920 1.081 0.796–1.466 0.618
Tertile 2 (anti‐inflammatory) 0.866 0.723–1.037 0.117 0.831 0.634–1.087 0.177
Tertile 3 (pro‐inflammatory) 1.0 (Reference)
NAFLD by LSM (kPa) cut‐off
Tertile 1 (anti‐inflammatory) 0.763 0.586–0.994 0.045 0.702 0.482–1.021 0.064
Tertile 2 (anti‐inflammatory) 0.817 0.629–1.059 0.127 0.766 0.559–1.049 0.097
Tertile 3 (pro‐inflammatory) 1.0 (Reference)
NAFLD by CAP (dB/m) cut‐off
Tertile 1 (anti‐inflammatory) 0.905 0.773–1.059 0.214 0.952 0.749–1.211 0.690
Tertile 2 (anti‐inflammatory) 1.038 0.885–1.217 0.646 0.994 0.802–1.232 0.957
Tertile 3 (pro‐inflammatory) 1.0 (Reference)
Note: The multivariable models were adjusted with sex, age, race, citizenship status, energy intake, alcohol intake, smoking, sedentary activity, hypertension, low HDL
levels, obesity and diabetes mellitus. In bold: p< 0.05.
Abbreviations: AST/ALT, aspartate aminotransferase/alanine aminotransferase; CAP, controlled attenuation parameter; CI, confidence interval; FLI, fatty liver index;
FIB‐4, fibrosis index based on four factors; HOMA‐IR, homeostatic model assessment‐insulin resistance; LSM, liver stiffness measurement.
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prevention of NAFLD in adults to prevent its progression to
advanced fibrosis. In agreement with our data, anti‐
inflammatory diets rich in omega‐3 polyunsaturated fatty
acids have been proposed as potential treatments for
NAFLD because they might enhance hepatic β‐oxidation,
decrease endogenous lipid production, and reduce the ex-
pression of pro‐inflammatory molecules and oxygen reactive
species.31 Interestingly, the results of a randomised double‐
blind placebo‐controlled trial demonstrated that a combined
treatment with α‐tocopherol (vitamin E) and vitamin C,
which are potent antioxidants with anti‐inflammatory
properties,32 resulted in a significant improvement in the fi-
brosis scores of participants after 6 months of therapy.33
Additionally, flavonoids, which act as potent antioxidants,
have been shown to exert beneficial effects against
NAFLD.34 Their protective effects are ascribed to their ca-
pacity to increase fatty acid oxidation in the liver and inhibit
nuclear factor‐kappa B, thereby attenuating the release of
inflammatory cytokines, which trigger insulin resistance, in-
crease adiponectin, and improve insulin sensitivity and glu-
cose tolerance.35
Similarly, in an analysis of participants in the Framing-
ham Heart Study, Mat et al.36 demonstrated that increasing
diet quality, based on the Mediterranean‐style diet score and
Alternative Healthy Eating Index score, is associated with
less liver fat accumulation and reduced risk for new‐onset
fatty liver. The protective effect of the Mediterranean dietary
pattern, a well‐known anti‐inflammatory dietary pattern,
against NAFLD may be driven by the high amounts of
MUFAs and phenolic compounds in olive oil, which exert
an anti‐inflammatory effect that has been associated with a
reduction in steatosis.37–39 Taken together, our results sug-
gest that an anti‐inflammatory diet exerts beneficial effects
on liver status. Thus, to slow the progression of fatty liver in
adults and reduce the comorbidities associated with the
disease, nutritional counseling and implementation of edu-
cational programs focused on the identification of anti‐
inflammatory and pro‐inflammatory foods are especially
relevant.
The present study has some limitations and strengths
that should be addressed. First, because of its cross‐
sectional nature, causality cannot be determined. There-
fore, longitudinal studies are necessary to analyse any effect
of the DII on liver status. Second, dietary intake was as-
sessed using a single 24‐h recall. This tool has been pro-
posed as a valuable method, although it may limit the
ability to accurately describe individuals’ habitual diets. In
addition, the DII score was determined based on only 26 of
the 45 food parameters in the original DII. Nevertheless,
previous studies have shown that the absence of these
missing components has no effect on DII scores because
they are not typically consumed by most population po-
pulations.40 Third, as a result of the lack of a liver biopsy
for the diagnostic confirmation of transient elastography
findings, we do not have the precise prevalence of NAFLD.
Additionally, it should be noted that the association be-
tween the lowest DII tertile and the FLI or AST:ALT ratio
may be related to changes in liver blood test results but
does not necessarily change the risk of liver‐related out-
comes over time. Further longitudinal studies would be
needed to clarify whether a lower DII changes the surrogate
markers of liver status or the liver status itself. By contrast,
the present study was strengthened by the inclusion of a
large nationally representative ethnically diverse population
and the use of transient elastography. The use of the highly
standardised procedures of the NHANES study, which
minimised measurement bias, was also a major strength.41
Future studies should concentrate on enhancing the quality
of the current topic.
In conclusion, there was no relationship between the
transient elastography parameters and the anti‐
inflammatory diet profile, although an anti‐inflammatory
diet was significantly associated with a lower AST:ALT
ratio and FLI score as surrogate measures of NAFLD
after adjusting for covariables, supporting the influence
of dietary inflammatory potential on liver status. Ad-
ditionally, the present study showed an association be-
tween higher pro‐inflammatory properties of diet and an
increased risk of NAFLD assessed by the FLI. Strategies
to promote an anti‐inflammatory diet should be con-
sidered to prevent NAFLD in adults. Future interven-
tion studies investigating the effect of dietary
inflammatory potential on LSM and CAP are required.
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